Market closed
Cabaletta Bio/$CABA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cabaletta Bio
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Ticker
$CABA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
163
ISIN
US12674W1099
Website
Cabaletta Bio Metrics
BasicAdvanced
$67M
-
-$2.36
2.58
-
Price and volume
Market cap
$67M
Beta
2.58
52-week high
$13.50
52-week low
$0.99
Average daily volume
787K
Financial strength
Current ratio
6.154
Quick ratio
6.053
Long term debt to equity
3.693
Total debt to equity
10.241
Interest coverage (TTM)
-167.30%
Management effectiveness
Return on assets (TTM)
-35.66%
Return on equity (TTM)
-59.64%
Valuation
Price to book
0.44
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-0.716
Growth
Earnings per share change (TTM)
42.95%
3-year earnings per share growth (CAGR)
9.49%
What the Analysts think about Cabaletta Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cabaletta Bio stock.
Cabaletta Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cabaletta Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cabaletta Bio News
AllArticlesVideos
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·1 month ago
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
Business Wire·2 months ago
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cabaletta Bio stock?
Cabaletta Bio (CABA) has a market cap of $67M as of May 15, 2025.
What is the P/E ratio for Cabaletta Bio stock?
The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of May 15, 2025.
Does Cabaletta Bio stock pay dividends?
No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Cabaletta Bio dividend payment date?
Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cabaletta Bio?
Cabaletta Bio (CABA) has a beta rating of 2.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.